Newsletter Tool

Today's Rundown

Pfizer accuses former employees of 'treachery' in stealing trade secrets to form Regor Therapeutics
Humana outlines its strategy to bounce back after MA growth for 2022 underwhelms
Pfizer's oral antiviral might be better, but Merck still expects $5B-plus from molnupiravir in 2022
Arrowhead ‘changing horses’ for ENaC pulmonary program as phase 1/2 asset shelved
After disastrous start to launch, Biogen still expects 'minimal' sales from Aduhelm this year
BD doubles COVID sales forecast for 2022 even as steep testing dropoff leads to revenue loss
HHS: Disparities in video telehealth use highlight key barriers to access
Completion of Lilly’s Alzheimer’s submission slips out of Q1 after CMS’ Aduhelm decision
Roche’s 2021 test sales collect on COVID demand, base business rebound
Takeda's Sequeira to head up newly created global portfolio division, Kim to lead US unit
City of Hope closes acquisition of Cancer Treatment Centers of America
Sanofi launches new corporate brand and logo, and that goes for Genzyme and Sanofi Pasteur, too
Quest CEO Rusckowski to step down after a decade, following record-setting 2021
Synaffix lines up $586M pact with MacroGenics en route to 'one-stop shop' for ADC tech

Featured Story

Pfizer accuses former employees of 'treachery' in stealing trade secrets to form Regor Therapeutics

By Annalee Armstrong

Pfizer has accused two former employees who went on to form a new biotech of stealing “the hard work” of the Big Pharma’s own scientists for a diabetes and obesity program, according to a lawsuit filed Wednesday.

Humana outlines its strategy to bounce back after MA growth for 2022 underwhelms

By Paige Minemyer

Humana posted a $14 million loss in the fourth quarter of 2021, according to the insurer's earnings report released Wednesday morning.

Pfizer's oral antiviral might be better, but Merck still expects $5B-plus from molnupiravir in 2022

By Kevin Dunleavy

Despite worries that Merck's oral COVID antiviral is inferior to Pfizer's rival drug, the Merck medicine is seeing demand amid the omicron surge. Merck execs project a big year for the medicine in 2022.

Arrowhead ‘changing horses’ for ENaC pulmonary program as phase 1/2 asset shelved

By Annalee Armstrong

Arrowhead Pharmaceuticals is ditching a pulmonary drug after it failed to hit the mark in a phase 1/2 cystic fibrosis trial last year. But the biotech is filling up its quiver with at least two more prospects in the program as a replacement.

After disastrous start to launch, Biogen still expects 'minimal' sales from Aduhelm this year

By Eric Sagonowsky

Before Biogen won approval for controversial Alzheimer's disease drug Aduhelm, the company had been facing down competitive threats to key medicines. Now that Aduhelm is on the market and barely generating any sales, the company could be in an even more challenging position than it was before.

BD doubles COVID sales forecast for 2022 even as steep testing dropoff leads to revenue loss

By Andrea Park

Nearly two full years into the pandemic, COVID-19 still has the power to make or break a company’s bottom line.

HHS: Disparities in video telehealth use highlight key barriers to access

By Robert King

A new federal survey found major disparities in video telehealth use across different incomes and ethnicities, sparking calls for new policies to create more equitable access.

Completion of Lilly’s Alzheimer’s submission slips out of Q1 after CMS’ Aduhelm decision

By Annalee Armstrong

The timeline for completing an accelerated approval request for Eli Lilly’s Alzheimer’s treatment donanemab has slipped out of the first quarter after the Centers for Medicare & Medicaid Services narrowed coverage for Biogen's rival med to just clinical trial use.

PM Tracker

Featured Story

Pfizer accuses former employees of 'treachery' in stealing trade secrets to form Regor Therapeutics

Top Stories

Humana outlines its strategy to bounce back after MA growth for 2022 underwhelms

Pfizer's oral antiviral might be better, but Merck still expects $5B-plus from molnupiravir in 2022

Arrowhead ‘changing horses’ for ENaC pulmonary program as phase 1/2 asset shelved

After disastrous start to launch, Biogen still expects 'minimal' sales from Aduhelm this year

BD doubles COVID sales forecast for 2022 even as steep testing dropoff leads to revenue loss

HHS: Disparities in video telehealth use highlight key barriers to access

Completion of Lilly’s Alzheimer’s submission slips out of Q1 after CMS’ Aduhelm decision

Roche’s 2021 test sales collect on COVID demand, base business rebound

Takeda's Sequeira to head up newly created global portfolio division, Kim to lead US unit

City of Hope closes acquisition of Cancer Treatment Centers of America

Sanofi launches new corporate brand and logo, and that goes for Genzyme and Sanofi Pasteur, too

Quest CEO Rusckowski to step down after a decade, following record-setting 2021

Synaffix lines up $586M pact with MacroGenics en route to 'one-stop shop' for ADC tech